{"id":3678,"date":"2024-05-15T13:54:41","date_gmt":"2024-05-15T04:54:41","guid":{"rendered":"https:\/\/bionauts.jp\/?p=3678"},"modified":"2024-05-19T23:56:06","modified_gmt":"2024-05-19T14:56:06","slug":"ahus-differential-diagnosis-method-kit","status":"publish","type":"post","link":"https:\/\/bionauts.jp\/?p=3678","title":{"rendered":"aHUS Differential Diagnosis Method\/Kit"},"content":{"rendered":"<h3>Advantages<\/h3>\n<ul>\n<li>aHUS differential diagnosis and remission monitoring, which was difficult with conventional methods, is possible.<\/li>\n<li>Responder to complement targeting drugs (anti-C5 antibodies, etc.) can be determined.<\/li>\n<\/ul>\n<h3>Background and Technology<\/h3>\n<p>Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy (TMA) and exhibits pathological conditions similar to secondary TMA such as collagen disease-related TMA. It differs from other TMA in that the cause is vascular endothelial cell damage due to disordered activation of genetic\/acquired complement, and it is a serious disease with a high risk of maintenance dialysis and death.<\/p>\n<p>The current diagnosis of aHUS is based on a combination of abnormalities in complement-related genes, the presence of anti-factor H antibodies, which are complement regulators, and clinical diagnosis. However, there are no clear criteria for diagnosis, and it is difficult to differentiate it from unsymptomatic genetic carriers and collagen disease-related TMA. The number of cases of aHUS occurring in Japan is approximately several dozen to several hundred cases per year, but the number of cases of collagen disease-related TMA, which is the subject of this differential diagnosis, is thought to be approximately 10,000 per year in Japan. The number of cases diagnosed with this may increase.<\/p>\n<p>For aHUS treatment, plasma therapy such as plasma exchange and anti-C5 antibody therapy, which is a complement targeting drug, are performed. Anti-C5 antibody drugs are highly effective against aHUS, but they are expensive treatments, and a definitive diagnosis of aHUS is required before use. It is also important to decide whether to discontinue medication when remission occurs.<\/p>\n<p>We have developed a plasma protein marker for aHUS, enabling differential diagnosis of aHUS and monitoring of patients during remission.<\/p>\n<table style=\"border-collapse: collapse; width: 44.3333%; height: 98px;\">\n<tbody>\n<tr>\n<td style=\"width: 100%;\"><a href=\"http:\/\/bionauts.jp\/wp-content\/uploads\/2024\/05\/BK-04011-1.png\"><img decoding=\"async\" loading=\"lazy\" class=\"alignleft size-full wp-image-3682\" src=\"http:\/\/bionauts.jp\/wp-content\/uploads\/2024\/05\/BK-04011-1.png\" alt=\"\" width=\"594\" height=\"394\" srcset=\"https:\/\/bionauts.jp\/wp-content\/uploads\/2024\/05\/BK-04011-1.png 594w, https:\/\/bionauts.jp\/wp-content\/uploads\/2024\/05\/BK-04011-1-300x199.png 300w\" sizes=\"(max-width: 594px) 85vw, 594px\" \/><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-size: 23px; font-weight: 900;\">Reference<\/span><\/p>\n<ul>\n<li>Patent pending (unpublished yet)<\/li>\n<\/ul>\n<h3>Principal Investigator<\/h3>\n<p>Noritoshi KATO (Department of Nephrology, Nagoya University Hospital)<\/p>\n<h3>Current Stage and Next Step<\/h3>\n<ul>\n<li>aHUS is a designated intractable disease in Japan, and Nagoya University operates the aHUS disease office and tests many patients. This method is the result of that research.<\/li>\n<li>Differential diagnosis and remission monitoring of aHUS can be a marker\/companion diagnostic for the development of complement-targeted drugs. We would like to promote collaboration between companies developing complement-targeted drugs and diagnostic drug companies.<\/li>\n<li>In the future, we plan to consider including this technology in the aHUS treatment guidelines and having it covered by insurance.<\/li>\n<li>We would also like to apply this technology to the differential diagnosis of other complement-related diseases (paroxysmal nocturnal hemoglobinuria, myasthenia gravis, neuromyelitis optica, collagen disease, etc.).<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>Project.BK-04011<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diagnostic kit for differentially diagnosing atypical hemolytic uremic syndrome (aHUS) from other thrombotic microangiopathy (TMA) using blood tests.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[1],"tags":[],"categories_of_inventions":[47],"disease_categories___indication":[],"asset_type":[],"development_phase":[],"medicine":[],"other_than_medicine":[127,128,130],"material":[],"engineering":[],"software_it":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts\/3678"}],"collection":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3678"}],"version-history":[{"count":4,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts\/3678\/revisions"}],"predecessor-version":[{"id":3684,"href":"https:\/\/bionauts.jp\/index.php?rest_route=\/wp\/v2\/posts\/3678\/revisions\/3684"}],"wp:attachment":[{"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3678"},{"taxonomy":"categories_of_inventions","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories_of_inventions&post=3678"},{"taxonomy":"disease_categories___indication","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fdisease_categories___indication&post=3678"},{"taxonomy":"asset_type","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fasset_type&post=3678"},{"taxonomy":"development_phase","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fdevelopment_phase&post=3678"},{"taxonomy":"medicine","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedicine&post=3678"},{"taxonomy":"other_than_medicine","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fother_than_medicine&post=3678"},{"taxonomy":"material","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmaterial&post=3678"},{"taxonomy":"engineering","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fengineering&post=3678"},{"taxonomy":"software_it","embeddable":true,"href":"https:\/\/bionauts.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fsoftware_it&post=3678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}